Healthcare CEOs are some of the most well-paid executives in the US.
We took a look at the compensation packages of the leaders overseeing some of the biggest healthcare companies.
Here’s how much they took home in 2018, according to regulatory filings.
Visit Business Insider’s homepage for more stories.
Leading a top healthcare company is a demanding job — and one for which CEOs are handsomely compensated.
There’s a lot that can come with the job title, from overseeing tens of billions of dollars in market value to testifying in front of Congress and finding ways to serve both shareholders and patients.
We took a look at the compensation packages of some of the leaders overseeing the largest healthcare companies. Included in packages were salaries, stock, and benefits like retirement and other incentives.
The pay packages range from single-digit millions to north of $26 million. Here’s how they stack up.
This article was originally published on April 22 and has been updated.
Allergan CEO Brent Saunders, $6,624,473
Brent Saunders has been presiding over Allergan and its billion-dollar Botox empire since 2014, when a $66 billion merger launched the company as a member of Big Pharma.
Lately, though, Saunders’ tenure has hit rocky times. Allergan still turns out a profitable business in cosmetics and eye care, but competition is also shaping up in those areas.
David Tepper’s Appaloosa LP hedge fund has slammed Allergan’s recent track record, calling for an independent board chair at the company — a move seen as an implicit critique of Saunders. Allergan’s stock price was among Appaloosa’s criticisms: It has steadily trended down since mid-2015, losing roughly 50% of its value.
Saunders’ leadership also came under attack in 2017, when he spearheaded an ill-advised gambit to extend patent protection on a key Allergan eye product, and last year, when a strategic review didn’t change much at the company.
Allergan’s market cap: $48 billion
GlaxoSmithKline CEO Emma Walmsley $7,662,210
Emma Walmsley has led the British drug giant GlaxoSmithKline for about two years, overseeing a time of transition for the company.
Like many of its pharmaceutical rivals, Glaxo is on the hunt for profitable new products that can sustain it for years to come.
Walmsley, who last year was one of just 25 female CEOs in the Fortune 500, comes to the world of healthcare by way of Glaxo’s consumer’s health business. Before joining …read more
Source:: Business Insider